Back to Oncology
OncologyvASTCT_2019Evidence-Based

Cytokine Release Syndrome (CRS) Grading

Assesses severity of cytokine release syndrome in immunotherapy patients, particularly those receiving CAR-T cell therapy and other immune effector cell therapies. CRS is an acute inflammatory process marked by a spectrum of clinical symptoms and substantial elevations of serum cytokines.

Clinical Input Parameters

years
Range: 0 — 120 years
Clinical Assessment
Awaiting Parameters
crs assessment
—grade
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Cytokine Release Syndrome (CRS) Grading is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

CRS Grade determined by highest severity parameter: fever requirement + maximum of (hypotension grade, oxygen requirement grade, organ toxicity grade)

Clinical Pearls & Practice Notes

  • Based on ASTCT (American Society for Transplantation and Cellular Therapy) consensus criteria
  • Fever ≥38°C required for Grade 1; not required for Grades 2-4 if anti-pyretic/anti-cytokine therapy given
  • Hypotension should be defined case-by-case considering patient's age and baseline
  • Organ toxicity graded using Common Terminology Criteria for Adverse Events (CTCAE)
  • Grade 4 transaminitis (liver toxicity) is considered Grade 3 CRS, not Grade 4
  • Requires specialized clinical expertise and frequent monitoring
  • Treatment should be individualized based on patient comorbidities and clinical status
  • Early recognition and prompt intervention are critical for optimal outcomes
  • Monitor for infection as immunosuppressive treatments may increase infection risk

Evidence & Literature Citations

  1. Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758.
  2. Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11(1):35. doi: 10.1186/s13045-018-0571-y.
  3. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47-62. doi: 10.1038/nrclinonc.2017.148.
  4. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20(2):119-122. doi: 10.1097/PPO.0000000000000035.

Score Interpretation Ranges

Grade 1 - Mild1 – 1 pts

Mild symptoms

Grade 2 - Moderate2 – 2 pts

Moderate intervention required

Grade 3 - Severe3 – 3 pts

Aggressive intervention required

Grade 4 - Life-threatening4 – 4 pts

Life-threatening symptoms

Grade 5 - Death5 – 5 pts

Death related to CRS

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.